Pharma Tariffs 2026: How 200% Duties Affect Drug Import Costs

On July 21, 2026, the administration announced a 200% tariff on imported generic drugs under Section 232 — and the headline immediately triggered a wave of patient questions: Will my medication get more expensive? Will my Ozempic cost more? What does this mean for my import costs?

Here is the part most coverage gets wrong: the 200% is the end of a phased timeline, not a rate that applies today. Generics face 0% duty until August 2028, then 100%, then 200% from August 2029 — unless manufacturers shift production to the U.S. in the window. Meanwhile, patented drugs already face a 100% duty under a separate April 2026 framework that took effect July 31, 2026. This page explains what was announced, what is already in force, which imports are affected, and how to estimate your own pharma import duty with the tariff calculator.

The 200% Tariff: What Was Announced (July 21, 2026)

The proposal targets generic drugs under Section 232, with a deliberate ramp designed to force pharmaceutical manufacturing back to the United States. The phased structure is the single most important fact to understand — and it is the fact most wire coverage blurs.

The phased timeline (0% → 100% Aug 2028 → 200% Aug 2029)

That ramp gives importers, CDMOs, and generic manufacturers a roughly two-year runway — but new U.S. plants are slow. A tablet plant takes 3–5 years to reach FDA-approved commercial supply, and injectables take longer. That timing gap is why analysts expect supply-chain disruption rather than a smooth reshoring curve.

Why it isn't final yet — no proclamation, no Federal Register notice

As of this writing, no implementing proclamation or Federal Register notice has been published for the generic-drug schedule. The scope of covered goods remains open — the administration has not yet specified whether the tariff covers active ingredients, biosimilars, short-supply drugs, or other categories. Until an annex of tariff lines is published, importers cannot legally rely on the 200% figure in customs filings; the operative rate for generics is still 0%.

What's Already in Effect: The 100% Patented-Drug Tariff

While the generic timeline is prospective, the patented-drug framework is live today. Proclamation 11020 (April 2, 2026; 91 FR 18183) imposed a 100% ad valorem duty on patented pharmaceuticals, biologics, and APIs/key starting materials, effective July 31, 2026 for most companies and September 29, 2026 for others.

Country rates: EU/Japan/Korea/Switzerland 15%, UK 10%, MFN deals 0%

The government cites a dependence problem as the driver: ~53% of patented pharma products distributed domestically are produced outside the U.S., and only ~15% of patented APIs by volume are produced domestically.

What's exempt — generics, biosimilars, orphan drugs, U.S.-origin, and more

The current framework exempts generics and biosimilars (for now), U.S.-origin goods, orphan drugs, nuclear medicines, plasma-derived therapies, fertility treatments, cell & gene therapies, antibody drug conjugates, CBRN countermeasures, and animal health products. For a full walkthrough of exemption categories and how to check your product, see our tariff exemption list.

Which Drugs and Imports Are Affected

Generics — 9 in 10 U.S. prescriptions

Generics account for 9 in 10 U.S. prescriptions, and their margins are thin. A 100% duty on top of Medicaid rebates, 340B pricing, and fixed contracts — where pass-through is largely blocked — risks discontinuation rather than reshoring. The drugs most likely to be dropped first: older injectables, cancer generics, long-established antibiotics, and single-manufacturer medicines that are already on the shortage radar.

Branded drugs and GLP-1s (Ozempic, Wegovy, Mounjaro)

Branded GLP-1s (Ozempic/Wegovy, Mounjaro/Zepbound) are patented, so they sit inside the 100% framework — but Lilly, Pfizer, and Novo Nordisk MFN pricing deals reportedly exempt them from tariffs for about three years. Lilly is building 4+ new U.S. manufacturing sites (~$27B, API + injectables); Novo's primary production is in Denmark. The unresolved exposure is compounded GLP-1 supply: the "ingredients" question in the generic proposal plus China's API dominance makes compounded semaglutide/tirzepatide a real risk vector even though branded pens are largely shielded.

APIs and ingredients — China's dominance

China supplies the chemistry: ~70% of chemical-based APIs used by Indian drugmakers and ~90% of biologic inputs. Whether the generic tariff covers ingredients is unresolved — if it does, the impact radiates far beyond finished tablets into every downstream formulation. See our China tariff rates explainer for the broader Section 301 picture.

How Tariffs Raise Drug Import Costs

Landed cost: duty + freight + what can and can't be passed through

Import cost isn't just the duty line. Landed cost = product value + duty + freight + insurance, and for pharma there's a second layer: contractual pass-through limits. Generic manufacturers with Medicaid rebates and 340B obligations often cannot pass a 100% duty through to buyers, which converts a tariff into a margin hit — and then a discontinuation decision. Run your own numbers with the tariff calculator to see the duty component on your product and origin country.

Who's most exposed: India ($9.7B to the U.S.), China, EU

India is the most exposed supplier: $25.8B in pharma exports worldwide in 2025, with $9.7B (37.7%) going to the U.S., and Indian companies supply roughly 47–50% of U.S. generic prescriptions. China is exposed through the API layer rather than finished generics. Europe is largely shielded — U.S.–EU terms mean European generics and ingredients pay close to nothing from September 1, 2026, so the tariff falls mostly on Asian suppliers.

Shortage risk: which drugs may be dropped instead of reshored

With a 3–5 year plant-approval timeline and thin generic margins, the realistic near-term response to a 100% duty is exit, not reshoring. Watch older injectables, cancer generics, long-established antibiotics, and single-manufacturer medicines — the same categories already flagged in U.S. shortage lists. For the country-level view on exposure, see our US tariff rates by country guide and the Section 301 tracker for related context.

Frequently Asked Questions

Sources: Proclamation 11020 (91 FR 18183); Crowell & Moring client alert (Section 232 pharma framework); CNBC (Jul 22, 2026); Pharmaceutical Online / Beroe July Update; Economic Times / GTRI; company announcements (Lilly, Novo Nordisk). Numbers verified against the research fact sheet dated August 2026; the generic schedule remains an unenacted announcement as of this page's publication.